文献速递消化道肿瘤与早癌

整合分析结直肠癌揭示跨队列肠道微生物特征及相关血清代谢物

Integrated Analysis of Colorectal Cancer Reveals Cross-Cohort Gut Microbial Signatures and Associated Serum Metabolites.
PubMed 文献 · Gastroenterology · 2022-07-01

该整合分析先在上海队列中鉴定结直肠癌相关微生物与代谢特征并训练微生物组合,在7个已发表宏基因组数据集中交叉验证;构建的微生物-代谢物联合诊断组合对腺瘤的曲线下面积为0.912、对结直肠癌为0.994,部分结直肠癌相关血清代谢物与跨队列微生物特征相关。

要点

  • 上海队列中鉴定结直肠癌相关肠道微生物与血清代谢改变,微生物组合在7个已发表宏基因组数据集中交叉验证。
  • 微生物-代谢物联合诊断组合诊断腺瘤的曲线下面积为0.912、诊断结直肠癌为0.994。
  • 结直肠癌富集的亮氨酰丙氨酸、血清素、咪唑丙酸及结直肠癌减少的全氟辛烷磺酸等代谢物与跨队列微生物特征相关。

核心结论

  • 研究获得了结直肠癌的跨队列宏基因组特征,其中部分特征与本研究结直肠癌相关血清代谢物相关联,微生物与代谢改变可能具有广泛人群相关性。

研究设计与样本

  • 整合宏基因组分析纳入健康对照91例、结直肠腺瘤63例、结直肠癌71例;代谢组分析纳入健康对照34例、结直肠腺瘤31例、结直肠癌35例,均来自上海队列。
  • 基于上海队列训练的肠道微生物组合在7个已发表结直肠癌宏基因组数据集中进行交叉验证。
  • 利用本研究代谢数据与跨队列微生物特征的联系推断可能具有外部相关性的血清代谢物,并构建诊断结直肠癌或腺瘤的微生物-代谢物联合组合。

主要发现

  • 在上海队列的肠道微生物组和血清代谢组中鉴定出结直肠癌相关改变。
  • 微生物-代谢物联合诊断组合诊断腺瘤的曲线下面积为0.912、诊断结直肠癌的曲线下面积为0.994。
  • 结直肠癌富集的亮氨酰丙氨酸、血清素和咪唑丙酸,以及结直肠癌减少的全氟辛烷磺酸、2-亚油酰甘油(18:2)和鞘氨二烯醇等代谢物与跨队列肠道微生物特征相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Studies have reported abnormal gut microbiota or circulating metabolome associated with colorectal cancer (CRC), but it remains a challenge to capture the CRC-relevant features consistent across geographic regions. This is particularly the problem for metabolic traits of CRC because the analyses generally use different platforms and laboratory methods, which poses a barrier to cross-dataset examination. In light of this, we sought to elucidate the microbial and metabolic signatures of CRC with broad population relevance. METHODS: In this integrated metagenomic (healthy controls [HC], n = 91; colorectal adenoma [CRA], n = 63; CRC, n = 71) and metabolomic (HC, n = 34; CRA, n = 31; CRC, n = 35) analysis, CRC-associated features and microbe-metabolite correlations were first identified from a Shanghai cohort. A gut microbial panel was trained in the in-house cohort and cross-validated in 7 published metagenomic datasets of CRC. The in-house metabolic connections to the cross-cohort microbial signatures were used as evidence to infer serum metabolites with potentially external relevance. In addition, a combined microbe-metabolite panel was produced for diagnosing CRC or adenoma. RESULTS: CRC-associated alterations were identified in the gut microbiome and serum metabolome. A composite microbe-metabolite diagnostic panel was developed and yielded an area under the curve of 0.912 for adenoma and 0.994 for CRC. We showed that many CRC-associated metabolites were linked to cross-cohort gut microbiome signatures of the disease, including CRC-enriched leucylalanine, serotonin, and imidazole propionate; and CRC-depleted perfluorooctane sulfonate, 2-linoleoylglycerol (18:2), and sphingadienine. CONCLUSIONS: We generated cross-cohort metagenomic signatures of CRC, some of which linked to in-house CRC-associated serum metabolites. The microbial and metabolic shifts may have wide population relevance.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Gao R, Wu C, Zhu Y, et al. Integrated Analysis of Colorectal Cancer Reveals Cross-Cohort Gut Microbial Signatures and Associated Serum Metabolites. Gastroenterology. 2022. PMID: 35788345. doi:10.1053/j.gastro.2022.06.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。